Contents 2 min read
Claim and source comparison
Alpha-GPC: an Alzheimer’s dementia trial, isometric strength and observational stroke data.
· Bounded source comparison; not a complete clinical review or independent medical endorsement.
Human randomized controlled trial
The 2003 trial enrolled 261 people with mild to moderate Alzheimer’s dementia. The trial assigned 132 to 400 mg of choline alfoscerate three times daily and 129 to placebo. At day 180, ADAS-Cog and MMSE scores were better in the choline alfoscerate group.
Scale scores in this patient group do not establish cognitive benefit in healthy people or slower disease progression.
Source 1 · Abstract read
Human randomized controlled trial
In a 2015 crossover trial, 13 young men received 600 mg/day of Alpha-GPC or placebo for 6 days per period. The lower-body isometric force test showed a difference. The difference on the upper-body test was not statistically significant.
This small, short trial did not measure cognition, muscle growth or long-term performance.
Source 3 · Full text read
Human observational study
In a 2021 cohort based on South Korean records for people aged 50 or older, Alpha-GPC prescriptions were associated with stroke. In the matched analysis, the adjusted hazard ratio for all strokes was 1.43 (95% confidence interval 1.41–1.46).
Prescription records may not fully reflect actual use. Underlying health differences could affect the association. This observational estimate does not establish causation or a person’s absolute risk.
Source 6 · Full text read
Correction · 2026-11-11. The Alzheimer’s trial groups were corrected. The general dose range, unverified side-effect threshold and wording on personal dose adjustment were removed.
What is Alpha-GPC?
Alpha-GPC and CDP-choline are different choline sources. Choline content by weight is not oral bioavailability; a clinical superiority ranking of 88%, 70%, 50% and 20% cannot be verified from these sources.
Mechanism of Effect
Choline is a precursor used in acetylcholine synthesis. The supply of choline from Alpha-GPC does not establish neuroprotection or cognitive improvement in humans.
Clinical Evidence
The 2003 trial enrolled 261 people with mild to moderate Alzheimer’s dementia. The trial assigned 132 to 400 mg of choline alfoscerate three times daily and 129 to placebo. At day 180, ADAS-Cog and MMSE scores were better in the choline alfoscerate group.
Ziegenfuss et al. (2008) published a conference abstract testing 600 mg Alpha-GPC 90 minutes before exercise in 7 men. The 44-fold peak GH rise was relative to baseline, not placebo; peak bench press force was 14% higher than placebo. This small acute study does not establish long-term muscle growth.
In a 2015 crossover trial, 13 young men received 600 mg/day of Alpha-GPC or placebo for 6 days per period. The lower-body isometric force test showed a difference. The difference on the upper-body test was not statistically significant.
Dose information and research limits
Dose information and research limits
This dose information describes research or product context; it is not a personal prescription, established safe upper limit or efficacy guarantee for healthy people. Extracts and different formulations should not be treated as equivalent milligram for milligram.
Safety and Side Effects
In a 2021 cohort based on South Korean records for people aged 50 or older, Alpha-GPC prescriptions were associated with stroke. In the matched analysis, the adjusted hazard ratio for all strokes was 1.43 (95% confidence interval 1.41–1.46).
Prescription records may not fully reflect actual use. Underlying health differences could affect the association. This observational estimate does not establish causation or a person’s absolute risk.
Related research and reading
These links show explicit editorial topic connections; they do not confirm a mechanism, efficacy or the safety of combined use. News dates refer to the source or event.
Educational guides
- Nootropic Stacks: Evidence and Risks of Five Combinations
Compare evidence and interaction risks for caffeine–L-theanine and other combinations; single-ingredient findings do not prove clinical synergy for every stack.
Sources
- De Jesus Moreno Moreno M. (2003). Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial. Clinical Therapeutics, 25(1), 178–193. PubMed · PMID 12637119
- Ziegenfuss T, Landis J, Hofheins J. (2008). Acute supplementation with alpha-glycerylphosphorylcholine augments growth hormone response to, and peak force production during, resistance exercise. Journal of the International Society of Sports Nutrition, 5(Suppl 1), P15. https://doi.org/10.1186/1550-2783-5-S1-P15 Conference poster · Springer Nature
- Bellar D, et al. (2015). The effect of 6 days of alpha glycerylphosphorylcholine on isometric strength. Journal of the International Society of Sports Nutrition, 12, 42. PubMed · PMID 26582972
- Parnetti L, et al. (2007). Cholinergic precursors in the treatment of cognitive impairment of vascular origin: ineffective approaches or need for re-evaluation? Journal of the Neurological Sciences, 257(1-2), 264–269. PubMed · PMID 17331541
- Canal N, et al. (1991). Effect of L-alpha-glyceryl-phosphorylcholine on amnesia caused by scopolamine. International Journal of Clinical Pharmacology, Therapy, and Toxicology, 29(3), 103–107. PubMed · PMID 2071257
- Lee G, et al. (2021). Association of L-α Glycerylphosphorylcholine With Subsequent Stroke Risk After 10 Years. JAMA Network Open, 4(11), e2136008. https://doi.org/10.1001/jamanetworkopen.2021.36008 PubMed · PMID 34817582
Link verification checks the identity of the publication; it does not constitute independent expert review of clinical claims. Our evidence and source methodology · Source directory
Frequently Asked Questions
Alpha-GPC is a choline source. It has been studied in Alzheimer’s disease and small exercise trials; cognitive benefits in healthy people and long-term safety remain uncertain.
Moreno’s Alzheimer trial used 1200 mg/day; Ziegenfuss’s 7-person exercise abstract tested a single 600 mg dose. These are not validated doses for healthy people or a choline-per-racetam ratio.
Lee et al. (2021) reported an association between Alpha-GPC prescriptions and higher 10-year stroke risk in a South Korean cohort aged 50 and older. This observational design cannot establish causation and disease-related confounding is possible; long-term use therefore cannot be described as risk-free.
Sale and import status in Türkiye must be checked for the specific product. Verify supplement approval in the Ministry of Agriculture and Forestry GGBS list, and medicine authorization and conditions of use in TİTCK records. Online availability does not establish approval or unrestricted personal import; current Ministry of Trade conditions apply to postal and express shipments.
No established timeframe